EDITORIAL
Alteplase for ischemic stroke: A giant with feet of clay?
First published: 03 August 2022
No abstract is available for this article.
CONFLICT OF INTEREST
None.
DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
REFERENCES
- 1Garg R. Methodological Survey of Missing Outcome Data in an Alteplase for Ischemic Stroke Meta-analysis. Acta Neurol Scand. 2022. doi:10.1111/ane.13656. Online ahead of print.
- 2Walsh M, Srinathan SK, McAuley DF, et al. The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index. J Clin Epidemiol. 2014; 67(6): 622-628.
- 3Stroke Thrombolysis Trialists' Collaborative Group. Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis. Int J Stroke. 2013; 8(4): 278-283.
- 4 National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333(24): 1581-1587.
- 5Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359(13): 1317-1329.
- 6Mann J. Truths about the NINDS study: setting the record straight. West J Med. 2002; 176(3): 192-194.
- 7Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 Update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019; 50(12): e344-e418.
- 8Hoffman JR. Thrombolysis for stroke: policy should be based on science, and not on politics, money or fear of malpractice. Emerg Med Australas. 2006; 18(3): 215-218.
- 9Hoffman JR, Schriger DL. A graphic reanalysis of the NINDS Trial. Ann Emerg Med. 2009; 54(3): 329-336. 336.e1-35.
- 10Donaldson L, Fitzgerald E, Flower O, Delaney A. Review article: Why is there still a debate regarding the safety and efficacy of intravenous thrombolysis in the management of presumed acute ischaemic stroke? A systematic review and meta-analysis. Emerg Med Australas. 2016; 28(5): 496-510.
- 11Meurer WJ, Barth B, Abraham M, Hoffman JR, Vilke GM, DeMers G. Intravenous recombinant tissue plasminogen activator and ischemic stroke: focused update of 2010 clinical practice advisory from the American academy of emergency Medicine. J Emerg Med. 2018; 54(5): 723-730.
- 12Alper BS, Foster G, Thabane L, Rae-Grant A, Malone-Moses M, Manheimer E. Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances. BMJ. Evid Based Med. 2020; 25(5): 168-171.
- 13Milne WK, Lang E, Ting DK, Atkinson P. CJEM Debate Series: #TPA should be the initial treatment in eligible patients presenting with an acute ischemic stroke. CJEM. 2020; 22(2): 142-148.
- 14Fatovich DM, Milne WK. Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances. BMJ Evid Based Med. 2021; 26(6): e2.
